Therapy of anemia and iron deficiency in dialysis patients: An update;Actualités sur la prise en charge de l'anémie et de la carence martiale du dialysé

Nephrologie et Therapeutique

Volumn 10, Issue 4, 2014, Pages 221-227

  Rostoker, Guy ^a   Hummel, Aurélie ^b   Chantrel, François ^c   Ryckelynck, Jean Philippe ^d  

^a Division of Nephrology and Dialysis Hôpital Privé Claude Galien Générale de Santé   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CENTRE HOSPITALIER DE MULHOUSE   (France)

^d CHU Clemenceau   (France)

Author keywords

ERBP; ESA; Hemosiderosis; IV iron; KDIGO; MRI

Indexed keywords

IRON; ANTIANEMIC AGENT; IRON DERIVATIVE;

ANEMIA; DRUG DOSE REGIMEN; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; QUANTITATIVE ANALYSIS; REVIEW; COMPLICATION; PRACTICE GUIDELINE; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

ANEMIA; HEMATINICS; HUMANS; IRON COMPOUNDS; IRON OVERLOAD; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84905254039     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2014.02.005     Document Type: Short Survey

References (37)

1. Kidney disease improving global outcomes (KDIGO) Clinical practice guideline for anemia in chronic kidney disease Kidney Int Suppl 2 2012 279 335
2. P. Fievet, M. Coppin, F. Brazier, M. Lefèvre, R. Stephan, and R. Demontis Traitement de la carence martiale en prédialyse par l'administration intraveineuse de doses élevées de fer dextran de bas poids moléculaire Nephrol Ther 8 2012 41 46
3. B. Rozen-Zvi, A. Gafter-Gvili, M. Paul, L. Leibovici, O. Shpilberg, and U. Gafter Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis Am J Kidney Dis 52 2008 897 906
4. S. Stancu, L. Barsan, A. Stanciu, and G. Mircescu Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5 2010 409 416
5. N. Tessitore, G.P. Solero, G. Lippi, A. Bassi, G.B. Faccini, and V. Bedogna et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin Nephrol Dial Transplant 16 2001 1416 1423 (Pubitemid 32640597)
6. D.W. Coyne, T. Kapoian, W. Suki, A.K. Singh, J.E. Moran, and N.V. Dahl et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to iv iron with elevated ferritin (DRIVE) study J Am Soc Nephrol 18 2007 975 984 (Pubitemid 46434515)
7. G. Rostoker, M. Griuncelli, C. Loridon, R. Couprie, A. Benmaadi, and C. Bounhiol et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis stimulating agents: a MRI study Am J Med 125 2012 991 999
8. P. Ferrari, H. Kulkarni, S. Dheda, S. Betti, C. Harrison, and T. St Pierre et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease Clin J Am Soc Nephrol 6 2011 77 83
9. H. Ghoti, E.A. Rachmilewitz, R. Simon- Lopez, R. Gaber, Z. Katzir, and E. Konen et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron Eur J Haematol 89 2012 87 93
10. N. Vaziri Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation Am J Med 125 2012 951 952
11. Agence nationale de sécurité du médicament et des produits de santé, (ANSM) Traitement de l'anémie des hémodialysés par solutions de fer IV: l'ANSM rappelle la nécessité de respecter les schémas posologiques de l'AMM 2012 [Point d'information du 18/02/2012]
12. KDOQI National Kidney Foundation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults Am J Kidney Dis 47 5 Suppl. 3 2006 Sl6 S85
13. F. Locatelli, A. Covic, K.U. Eckardt, A. Wiecek, and R. Vanholder Anemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European renal best practice (ERBP) Nephrol Dial Transplant 24 2009 348 354
14. NICE clinical guideline 39 Anemia management in people with chronic kidney disease 2011 [Issue September 2006, rapid update 2011]
15. H. Yamamoto, and Y. Tsubakihara Limiting iron supplementation for anemia in dialysis patients: the basis for Japan's conservative guidelines Semin Dial 24 2011 269 271
16. M. Ali, R. Rigolosi, A.O. Fayemi, E. Braun, J. Frascino, and R. Singer Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy Lancet 1 1982 652 655 (Pubitemid 12179936)
17. J.C. Barton, C.Q. Edwards, P.D. Phatak, R.S. Britton, and B.R. Bacon Handbook of iron overload disorders 2010 Cambridge University Press Cambridge
18. Y. Gandon, D. Olivie, D. Guyader, C. Aubé, F. Oberti, and V. Sebille et al. Non-invasive assessment of hepatic iron stores by MRI Lancet 363 2004 357 362 (Pubitemid 38169542)
19. J.M. Alustiza, J. Artetexte, A. Castiella, J. Emparanza, P. Otazua, and M. Garcia-Bengoechea et al. MRI quantification of hepatic iron concentration Radiology 230 2004 479 484 (Pubitemid 38133810)
20. T.G. Saint-Pierre, P.R. Clark, W. Chua-Anusom, A.J. Fleming, G.P. Jeffrey, and J.K. Olynyk et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonnace Blood 105 2005 855 861 (Pubitemid 40070775)
21. A. Meloni, H.Y. Reinhoff Jr., A. Jones, A. Pepe, M. Lombardi, and J. Wood The use of appropriate calibration curves correct for systematic differences in liver R2* values measured using different software packages Br J Haematology 161 2013 888 891
22. C. Canavese, D. Bergamo, G. Ciccone, F. Longo, F. Fop, and A. Thea et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients Kidney Int 65 2004 1091 1098 (Pubitemid 38251085)
23. S. Fishbane, N. Miyawaki, and N. Massani Hepatic iron in hemodialysis patients Kidney Int 66 2004 1714 1715
24. 52 Fe-labelled iron (III) hydroxyde-sucrose complex following bolus administration using positon emission tomography Br J Haematol 104 1999 288 295 (Pubitemid 29083336)
25. S.P. Ramirez Anemia care is changing dramatically: potential implications of higher iron dosing 2012 American Society of Nephrology, Annual meeting San Diego, California
26. B. Robinson DOPPS practice monitor: most recent trends in dialysis practice in the US bundled rate era 2012 American Society of Nephrology, Annual meeting San Diego, California
27. M.A. Brookhart, J.K. Freburger, A.R. Ellis, L. Wang, W. Winkelmayer, and A.V. Kshirsagar Infection risk versus maintenance iron supplementation in hemodialysis patients J Am Soc Nephrol 24 2013 1151 1158
28. J.W. Eschbach, J.D. Cook, and C.A. Finch Iron absorption in chronic renal disease Clin Sci 38 1970 191 196
29. J. Albaramki, E.M. Hodson, J.C. Craig, and A.C. Webster Parenteral versus oral iron therapy for adults and children with chronic kidney disease Cochrane Database Syst Rev 1 2012 CD007857
30. D.B. Bregman, D. Morris, T.A. Koch, A. He, and L.T. Goodnough Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia Am J Hematol 88 2013 97 101
31. Agence nationale de sécurité du médicament et des produits de santé (ANSM) Spécialités à base de fer pour injection intraveineuse: une utilisation réservée aux établissements de santé en raison du risque de réactions graves d'hypersensibilité 2013 [Point d'information de l'ASNM du 06/11/2013]
32. F. Locatelli, P. Barany, A. Covic, A. De Francisco, L. Del Vecchio, and D. Goldsmith et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement Nephrol Dial Transplant 28 2013 1346 1359
33. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. de Zeeuw, and K.U. Eckardt et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
34. T.B. Drueke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Mcdougall, and D. Tsakiris et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084 (Pubitemid 44749316)
35. S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, M. Tonelli, and A.X. Garg et al. Meta-analysis: erythropoiesis- stimulating agents in patients with chronic kidney disease Ann Intern Med 153 2010 23 33
36. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, and D.M. Okamoto et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590 (Pubitemid 28385655)
37. F. Carrera, C.E. Lok, A. de Francisco, F. Locatelli, J.F. Mann, and B. Canaud et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial Nephrol Dial Transplant 25 2010 4009 4017